Abstract
Treatment of melanoma with immune checkpoints inhibitors .Immunotherapy with checkpoints inhibitors stimulates the anti-tumor response. It has dramatically changed the prognosis of advanced melanoma and other cancers. Anti-PD1, alone or in combination with anti-CTLA4, has demonstrated significantly better response and overall survival rates than chemotherapy. The immuno-mediated toxicity is more frequent and more serious with the combination of anti-PD1 and anti-CTLA4, which also appears as the most effective treatment for metastatic melanoma. Adjuvant anti-PD1 therapy is also effective in preventing recurrence in patients with resected stage III or IV melanoma. Studies are underway to evaluate this treatment in a neo-adjuvant situation and in localized melanomas with high risk of recurrence (stage II) with promising results.
| Translated title of the contribution | Treatment of melanoma with immune checkpoints inhibitors |
|---|---|
| Original language | French |
| Pages (from-to) | 380-383 |
| Number of pages | 4 |
| Journal | Revue du Praticien |
| Volume | 71 |
| Issue number | 4 |
| Publication status | Published - 1 Apr 2021 |